GET DAILY SIGNALSMetaVia (MTVA) Near $1.43 After -2% Monthly Move: Clinical Catalysts in Focus
Key Takeaways
- MetaVia (MTVA) shares traded near $1.43 in early November 2026, down roughly 2% over the trailing 30 days.
- The stock remains highly volatile, with a 52-week range of approximately $0.97 to $13.42 and sharp single-session swings on elevated volume.
- MetaVia is a clinical-stage biotechnology company advancing two lead cardiometabolic candidates: DA-1241 (vanoglipel) for MASH and type 2 diabetes, and DA-1726 for obesity.
- The company reported positive topline data from its DA-1726 Phase 1 48 mg multiple-ascending-dose cohort in January 2026.
- As a pre-revenue developer, MetaVia depends on capital raises and reported roughly $12.6 million in cash in its most recent quarter.
- Investors closely track clinical milestones, FDA interactions, and the broader competitive landscape for obesity and metabolic therapies.
- For additional data, explore MetaVia's Price Targets, Earnings, and Forecast pages.
- For systematic, data-driven trading ideas, explore Trending AI Robots.
Current Market Snapshot
MetaVia (MTVA) trades on the Nasdaq Capital Market as a low-priced, micro-cap biotechnology name with a market capitalization of roughly $9 million. The shares have demonstrated outsized volatility, moving within a 52-week range of about $0.97 to $13.42, with a five-year monthly beta near 1.24. In the trailing 30 days, the stock declined about 2%, but that modest net move masks sharp intraday swings, including a pronounced selloff followed by a strong rebound on unusually heavy volume in early November.
Because MetaVia generates no product revenue, its share price is driven primarily by clinical trial results, regulatory updates, financing activity, and sentiment around the obesity and metabolic-disease sector rather than by traditional earnings fundamentals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
MetaVia (MTVA) Business Overview and Competitive Position
MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. The company was previously known as NeuroBo Pharmaceuticals and traded under the ticker NRBO before rebranding as MetaVia and adopting the MTVA symbol in November 2024.
The pipeline is anchored by two lead programs. DA-1241 (vanoglipel) is a GPR119 agonist being evaluated for metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes, with optionality as a standalone or combination therapy. DA-1726 is an oxyntomodulin analog functioning as a GLP-1 and glucagon receptor dual agonist designed as a once-weekly subcutaneous treatment for obesity. The company is also pursuing out-licensing or divestiture opportunities for several legacy programs outside its core cardiometabolic focus.
MetaVia competes in a heavily funded and rapidly evolving therapeutic area dominated by established GLP-1 and metabolic franchises. Its competitive positioning relies on differentiating its candidates through mechanism, dosing profile, and clinical data rather than on commercial scale, given its pre-revenue status and small operating footprint.
Recent Developments Driving MTVA
Several clinical and corporate milestones have shaped investor sentiment around MTVA. In January 2026, MetaVia announced positive topline data from the non-titrated 48 mg Cohort 5 of its Phase 1 multiple-ascending-dose trial of DA-1726, extending earlier single-ascending-dose and multiple-ascending-dose results reported in 2024 and 2025. In November 2025, the company presented new Phase 1 and preclinical data on DA-1726 in poster presentations at ObesityWeek 2025.
On the DA-1241 program, MetaVia has been finalizing the clinical study report for a Phase 2a trial in presumed MASH, for which positive 16-week topline results were announced in December 2024, and is working toward an end-of-Phase 2 meeting with the FDA. These regulatory and data milestones remain central to the stock's narrative.
Financing activity has also been a recurring theme. As a pre-revenue company, MetaVia has relied on equity offerings and at-the-market programs to fund operations, and its cash position is a key point of investor focus. The company's common stock has been subject to significant dilution and price volatility as it raises capital to advance its pipeline.
2026 Outlook and What Investors Should Watch
Looking ahead, MetaVia's trajectory will likely hinge on clinical execution and regulatory progress. Key catalysts include the end-of-Phase 2 meeting with the FDA for DA-1241 in MASH, further readouts and dose-escalation data from the DA-1726 program, and any advancement toward later-stage trials. Data presentations at major medical conferences could also influence sentiment.
On the financial side, investors will monitor the company's cash runway, the terms and timing of any additional capital raises, and dilution from outstanding warrants and equity programs. Macroeconomic conditions, including interest-rate expectations and risk appetite for small-cap and pre-revenue biotech names, may also affect the stock's valuation.
Competitive developments across the broader obesity and metabolic-disease landscape remain an ongoing risk, as larger players continue to invest heavily in the same therapeutic areas. MetaVia's ability to differentiate DA-1726 and DA-1241 on efficacy, safety, and dosing will be critical to its long-term prospects.
Integrating AI Tools Into My Research
In my own work, I often turn to Tickeron’s Trending AI Robots for a focused look at automated strategies that cover thousands of tickers. The page surfaces top-performing bots across different timeframes and approaches, letting me compare metrics side by side. This gives an extra layer of systematic perspective when evaluating names like MTVA alongside my fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MTVA in downward trend: 10-day moving average broke below 50-day moving average on October 07, 2026
The 10-day moving average for MTVA crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MTVA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MTVA's RSI Indicator exited the oversold zone, 37 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where MTVA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MTVA as a result. In 73 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for MTVA just turned positive on November 04, 2026. Looking at past instances where MTVA's MACD turned positive, the stock continued to rise in 30 of 38 cases over the following month. The odds of a continued upward trend are 79%.
Following a +14.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTVA advanced for three days, in 181 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
MTVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.381) is normal, around the industry mean (3.498). P/E Ratio (-0.584) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. MTVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement